[Adjuvant local BCG-immunotherapy in patients with urothel cancer of the bladder (author's transl)].
45 patients with urothel cancer of the bladder were examined clinically and immunologically and treated after transurethral resection with intravesical application of BCG as active unspecific immune therapy. The results of immunological cutaneous tests and the grade of peritumoral infiltration with immune competent cells were compared with histological grading and staging of the tumour. No significant relation between the results could be found. In a 2.5 years follow-up period a persistent tumour was found in 36% and a recurrence of the tumour in 59% of the patients. The intravesical instillation of BCG did not improve the prognosis. From the results of the immunological cutaneous tests together with the staging and grading of the tumour no reliable prediction of prognosis is possible.
D000368:Aged; D001500:BCG Vaccine / Q000627:therapeutic use*; D002295:Carcinoma, Transitional Cell / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D005260:Female; D006801:Humans; D007111:Immunity, Cellular; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D001743:Urinary Bladder / Q000601:surgery; D001749:Urinary Bladder Neoplasms / Q000276:immunology / Q000473:pathology / Q000628:therapy*
D001500:BCG Vaccine
Adjuvante lokale Immunotherapie mit Bacillus Calmette-Guérin (BCG) in der Behandlung des Urothelkarzinoms der Harnblase.